Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Ruktanonchai D[original query] |
---|
Best practices in availability, management and use of geospatial data to guide reproductive, maternal, child and adolescent health programmes
Molla YB , Nilsen K , Singh K , Ruktanonchai CW , Schmitz MM , Duong J , Serbanescu F , Moran AC , Matthews Z , Tatem AJ . BMJ Glob Health 2019 4 e001406 The commentary provides a set of considerations and some examples for reproductive, maternal, newborn, child and adolescent health (RMNCAH) programmes that wish to use geospatial data. | Monitoring RMNCAH data trends or change over time and estimating disease burden remain major challenges due to limited reliable geolocated data sources, inconsistent spatial denominators and technical capacity needs. | Increased availability of spatial data, such as satellite imagery and geolocated survey and facility data, coupled with recent methodological refinements, has created new opportunities for use of geographic information systems to achieve spatial disaggregation of RMNCAH data and highlights subnational monitoring among vulnerable populations. | More refined geospatial analyses can help to close the gap for countries with high maternity-related deaths and suffering. |
Effect of aerial insecticide spraying on West Nile virus disease - north-central Texas, 2012
Ruktanonchai DJ , Stonecipher S , Lindsey N , McAllister J , Pillai SK , Horiuchi K , Delorey M , Biggerstaff BJ , Sidwa T , Zoretic J , Nasci R , Fischer M , Hills SL . Am J Trop Med Hyg 2014 91 (2) 240-5 During 2012, four north-central Texas counties experienced high West Nile virus (WNV) disease incidence. Aerial insecticide spraying was conducted in two counties. To evaluate the effect of spraying on WNV disease, we calculated incidence rate ratios (IRRs) in treated and untreated areas by comparing incidence before and after spraying; for unsprayed areas, before and after periods were defined by using dates from a corresponding sprayed area. In treated areas, WNV neuroinvasive disease incidence before and after spraying was 7.31/100,000 persons and 0.28/100,000 persons, respectively; the IRR was 26.42 (95% confidence interval [CI]: 12.42-56.20). In untreated areas, the before and after incidence was 4.80/100,000 persons and 0.45/100,000 persons, respectively; the IRR was 10.57 (95% CI: 6.11-18.28). The ratio of IRRs was 2.50 (95% CI: 0.98-6.35). Disease incidence decreased in both areas, but the relative change was greater in aerial-sprayed areas. |
Zinc deficiency-associated dermatitis in infants during a nationwide shortage of injectable zinc - Washington, DC, and Houston, Texas, 2012-2013
Ruktanonchai D , Lowe M , Norton SA , Garret T , Soghier L , Weiss E , Hatfield J , Lapinski J , Abrams S , Barfield W . MMWR Morb Mortal Wkly Rep 2014 63 (2) 35-7 Injectable zinc, a vital component of parenteral nutrition (PN) formulations, has been in short supply in the United States since late 2012. In December 2012, three premature infants with cholestasis hospitalized in Washington, DC, experienced erosive dermatitis in the diaper area and blisters on their extremities, a condition that can be associated with zinc deficiency. All three infants were receiving PN because they had extreme cholestasis and were unable to be fed by mouth or tube. The PN administered to each infant was zinc deficient. Injectable zinc normally is added to PN for premature or medically compromised infants (e.g., those with cholestasis) by the hospital pharmacy because the amount of zinc needed by each patient differs; however, the pharmacy had run out of injectable zinc. No alternatives were available; other preparations of parenteral trace elements either contained insufficient zinc to meet infants' requirements or had the potential to cause trace element toxicity in infants with cholestasis (2). The dermatitis of one infant resolved after the patient was able to take nutrition by mouth. The other two infants were found to have low serum zinc levels. In January 2013, CDC was notified of four additional cases of zinc deficiency among infants with cholestasis who received zinc-deficient PN in a hospital in Houston, Texas. In collaboration with the Food and Drug Administration (FDA), the two hospitals obtained emergency shipments of injectable zinc. No additional cases were reported. Current injectable zinc supplies have been increasing as FDA collaborates with pharmaceutical companies to import emergency supplies. FDA is working to establish temporary backup sources should future shortages occur. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure